A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-017-0499-6"><b>here</b>.</a><br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact <u>[email protected]</u>.<br> <br> The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br> <br> Other enhanced features include, but are not limited to:<br> • Slide decks<br> • Videos and animations<br> • Audio abstracts<br> • Audio slides<u></u></p

Additional file 2: Figure S2. of A donor splice site mutation in CISD2 generates multiple truncated, non-functional isoforms in Wolfram syndrome type 2 patients

Chromatograms of the 400 nt-5′-RACE products not subjected to subcloning. (TIFF 155 kb

Clinical characteristics of study patients on the basis of the presence/ absence of metabolic syndrome and hyperuricemia (top gender-specific quintile).

<p>Clinical characteristics of study patients on the basis of the presence/ absence of metabolic syndrome and hyperuricemia (top gender-specific quintile).</p

A unique plasma microRNA profile defines type 2 diabetes progression

<div><p>A major unmet medical need to better manage Type 2 Diabetes (T2D) is the accurate disease prediction in subjects who show glucose dysmetabolism, but are not yet diagnosed as diabetic. We investigated the possibility to predict/monitor the progression to T2D in these subjects by retrospectively quantifying blood circulating microRNAs in plasma of subjects with i) normal glucose tolerance (NGT, n = 9); ii) impaired glucose tolerance (IGT, n = 9), divided into non-progressors (NP, n = 5) and progressors (P, n = 4) based on subsequent diabetes occurrence, and iii) newly diagnosed T2D (n = 9). We found that impaired glucose tolerance associated with a global increase of plasma circulating microRNAs. While miR-148 and miR-222 were specifically modulated in diabetic subjects and correlated with parameters of glucose tolerance, the most accentuated microRNA dysregulation was found in NP IGT subjects, with increased level of miR-122, miR-99 and decreased level of let-7d, miR-18a, miR-18b, miR-23a, miR-27a, miR-28 and miR-30d in comparison with either NGT or T2D. Interestingly, several of these microRNAs significantly correlated with parameters of cholesterol metabolism. In conclusion, we observed the major perturbation of plasma circulating microRNA in NP pre-diabetic subjects and identified a unique microRNA profile that may become helpful in predicting diabetic development.</p></div

Dysregulation of plasma circulating miRNAs in glucose tolerance impaired subjects.

<p>(A) Boxplots (10–90 percentile) for the number of detected miRNAs (left) and miRNA Ct values (right) in the three indicated sample groups. Non-parametric Kruskal-Wallis p-values are reported at the bottom of the graph, while Dunn’s multiple comparison test (<i>versus</i> NGT group) p-values are reported on single group plots (* <0.05; ** <0.01; *** <0.001). (B) Scatter plots showing the correlation between miRNA global means (for the 27 individuals belonging to the three groups of NGT, IGT and T2D) expressed as reversed Ct values and either oral glucose tolerance test (OGTT, that refers to glucose level measured 2 hours post load, left) or glycated hemoglobin (HbA1c, right). Spearman correlation coefficient r and p-values are also reported. (C) Boxplot for single miRNA non-parametric correlation with the global mean values, averaged per group. Non-parametric Kruskal-Wallis p-value is reported at the bottom of the graph. Dunn’s multiple comparison test (<i>versus</i> IGT group) p-values are shown (* <0.05; *** <0.001). (D) Heatmap reporting the correlation index map (non parametric Spearman r values) of each co-expressed miRNA <i>versus</i> all the others. The map is divided per group as indicated. (E) Vertical scatter plots for Log10 transformed global mean normalized miRNA values in the three groups as indicated. The IGT group is divided in two further groups: progressors (P IGT) and non-progressors (NP IGT), based on their clinical history (see text). miRNAs were found differentially expressed in at least one group comparisons (t Test p-value<0.05, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0188980#pone.0188980.t002" target="_blank">Table 2</a>). (F) Hierarchical clustering of the four groups (the IGT group being divided as in panel E) using the Log10 transformed normalized values of differentially expressed miRNAs (as for panel E).</p

Determinants of measures of renal outcome including the presence/absence of Metabolic Syndrome and/or Hyperuricemia.

<p>Determinants of measures of renal outcome including the presence/absence of Metabolic Syndrome and/or Hyperuricemia.</p

Clinical data.

<p>Clinical data.</p

1A. The abundance of α(1,6)-arm monogalactosylated, core-α-1,6-fucosylated diantennary glycan NG1(6)A2F, assessed by peak 3 (P3) levels, in CTR and T2DM patients with and without MS.

<p>The boxplots represent a comparison of peak 3 levels in males in six classes of subjects: CTR without MS, CTR with MS, T2DM- without MS, T2DM- with MS, T2DM+ without MS, T2DM+ with MS. <b>1B.</b> The abundance of α(1,6)-arm monogalactosylated, core-α-1,6-fucosylated diantennary glycan NG1(6)A2F, assessed by peak 3 (P3) levels, in CTR and T2DM patients with and without MS. The boxplots represent a comparison of peak 3 levels in females in six classes of subjects: CTR without MS, CTR with MS, T2DM- without MS, T2DM- with MS, T2DM+ without MS, T2DM+ with MS.</p

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study

<h2>Article full text</h2><p>The full text of this article can be found here <a href="https://link.springer.com/article/10.1007/s12325-017-0652-2">https://link.springer.com/article/10.1007/s12325-017-0652-2</a>.</p><h2>Provide enhanced content for this article</h2><p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”">[email protected]</a>.</p><p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p><p>Other enhanced features include, but are not limited to:</p><ul><li>Slide decks</li><li>Videos and animations</li><li>Audio abstracts</li><li>Audio slides</li></ul